Whittier Trust Co. of Nevada Inc. boosted its stake in shares of Pfizer, Inc. (NYSE:PFE) by 2.1% during the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm owned 297,119 shares of the biopharmaceutical company’s stock after buying an additional 6,229 shares during the period. Pfizer makes up about 1.0% of Whittier Trust Co. of Nevada Inc.’s portfolio, making the stock its 24th largest position. Whittier Trust Co. of Nevada Inc.’s holdings in Pfizer were worth $9,980,000 as of its most recent filing with the SEC.

Other institutional investors have also recently modified their holdings of the company. Asset Planning Services Ltd. increased its position in shares of Pfizer by 4.9% in the first quarter. Asset Planning Services Ltd. now owns 2,961 shares of the biopharmaceutical company’s stock valued at $101,000 after buying an additional 137 shares during the last quarter. D. Scott Neal Inc. increased its position in shares of Pfizer by 19.3% in the second quarter. D. Scott Neal Inc. now owns 3,112 shares of the biopharmaceutical company’s stock valued at $105,000 after buying an additional 504 shares during the last quarter. Orrstown Financial Services Inc. increased its position in shares of Pfizer by 23.0% in the first quarter. Orrstown Financial Services Inc. now owns 3,275 shares of the biopharmaceutical company’s stock valued at $112,000 after buying an additional 612 shares during the last quarter. Franklin Parlapiano Turner & Welch LLC purchased a new position in shares of Pfizer during the first quarter valued at approximately $121,000. Finally, Cascade Investment Advisors Inc. increased its position in shares of Pfizer by 89.1% in the second quarter. Cascade Investment Advisors Inc. now owns 4,669 shares of the biopharmaceutical company’s stock valued at $157,000 after buying an additional 2,200 shares during the last quarter. Institutional investors own 69.94% of the company’s stock.

Pfizer, Inc. (PFE) traded down 0.85% during midday trading on Friday, reaching $32.67. 15,490,145 shares of the company were exchanged. The firm has a 50-day moving average price of $33.30 and a 200-day moving average price of $33.38. Pfizer, Inc. has a 52 week low of $29.83 and a 52 week high of $35.38. The company has a market capitalization of $194.30 billion, a PE ratio of 23.90 and a beta of 1.00.

Pfizer (NYSE:PFE) last released its quarterly earnings results on Tuesday, August 1st. The biopharmaceutical company reported $0.67 EPS for the quarter, beating the consensus estimate of $0.65 by $0.02. Pfizer had a net margin of 15.84% and a return on equity of 24.51%. The firm had revenue of $12.90 billion during the quarter, compared to the consensus estimate of $13.08 billion. During the same quarter in the prior year, the firm earned $0.64 EPS. Pfizer’s revenue for the quarter was down 1.9% on a year-over-year basis. Equities research analysts anticipate that Pfizer, Inc. will post $2.56 earnings per share for the current fiscal year.

The firm also recently declared a quarterly dividend, which will be paid on Friday, September 1st. Investors of record on Friday, August 4th will be given a $0.32 dividend. The ex-dividend date is Wednesday, August 2nd. This represents a $1.28 annualized dividend and a yield of 3.92%. Pfizer’s dividend payout ratio (DPR) is 94.12%.

ILLEGAL ACTIVITY NOTICE: This piece was posted by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are viewing this piece on another domain, it was illegally copied and reposted in violation of international trademark and copyright laws. The original version of this piece can be viewed at https://www.thecerbatgem.com/2017/08/20/whittier-trust-co-of-nevada-inc-has-9-98-million-position-in-pfizer-inc-pfe.html.

Several brokerages recently commented on PFE. Citigroup Inc. downgraded shares of Pfizer from a “neutral” rating to a “sell” rating and cut their price target for the company from $38.00 to $31.00 in a report on Tuesday, May 16th. BidaskClub upgraded shares of Pfizer from a “strong sell” rating to a “sell” rating in a report on Saturday, August 5th. Jefferies Group LLC set a $35.00 target price on shares of Pfizer and gave the stock a “neutral” rating in a research note on Wednesday, August 2nd. BMO Capital Markets upgraded shares of Pfizer from a “market perform” rating to an “outperform” rating and upped their target price for the stock from $33.00 to $37.00 in a research note on Wednesday, August 2nd. Finally, Barclays PLC restated a “buy” rating and issued a $38.00 target price on shares of Pfizer in a research note on Wednesday, May 3rd. Two analysts have rated the stock with a sell rating, eleven have given a hold rating and ten have given a buy rating to the stock. The stock has a consensus rating of “Hold” and a consensus price target of $37.61.

In other Pfizer news, CEO Ian C. Read sold 96,950 shares of the company’s stock in a transaction on Friday, August 4th. The shares were sold at an average price of $34.00, for a total transaction of $3,296,300.00. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, insider Alexander R. Mackenzie sold 15,000 shares of the company’s stock in a transaction on Monday, August 7th. The stock was sold at an average price of $33.50, for a total transaction of $502,500.00. Following the transaction, the insider now owns 151,474 shares of the company’s stock, valued at approximately $5,074,379. The disclosure for this sale can be found here. 0.06% of the stock is owned by corporate insiders.

About Pfizer

Pfizer Inc (Pfizer) is a research-based global biopharmaceutical company. The Company is engaged in the discovery, development and manufacture of healthcare products. Its global portfolio includes medicines and vaccines, as well as consumer healthcare products. The Company manages its commercial operations through two business segments: Pfizer Innovative Health (IH) and Pfizer Essential Health (EH).

Institutional Ownership by Quarter for Pfizer (NYSE:PFE)

Receive News & Stock Ratings for Pfizer Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfizer Inc. and related stocks with our FREE daily email newsletter.